The Department of Pharmaceuticals (DOP) of India has issued a draft policy designed to reduce the time for drug approval, reduce reliance on China on raw materials, increase the number of drug compounds found in India and focus on Indian drug quality. According to The Wire, the government would also shifts from using price controls on the pharmaceutical industry but wants to practice "one company–one drug–one brand name–one price." The Wire says "this approach did not help the affordability of drugs and this led the government to make active interventions via price control." The Indian judiciary had already challenged this approach to big pharma in 2002. What do you think about India's new direction?
Search
Crystal Foretia
Aug 21, 2017
New Pharma Policy in India
New Pharma Policy in India
1 comment
The general idea of making drugs more affordable and accessible seems to be quite positive. It's interesting, as the article mentions, that very few countries do not have governments involved in drug price legislation.